On March 6, 2018 Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQB: OGRMF), a leading licensed producer of medical marijuana based in Moncton, New Brunswick, announced that it had received Health Canada approval for the remaining 13 rooms of its 23 room Phase 2 expansion a week ahead of schedule. The Company expects harvests from the Phase 2 expansion to begin the third week of April.
The Phase 2 expansion will reportedly include significant improvements and efficiencies to the company’s cultivation and processing systems. Planned enhancements will include a fully automated irrigation system, automated potting, a fully automated waste destruction system and automated packaging. Organigram’s approach to production has been trending yields that are in some cases 50% higher than its previous estimates and the company fully anticipates this to continue with enhanced improvements in cultivation and environmental design in Phase 3 and Phase 4 as well as through achievements of economies of scale through optimization of its pre-vegetation and cloning processes.
According to Organigram CEO, Greg Engel, the company is, “seeing some harvest yields that are more than 400 grams per square foot a year and have witnessed the quality, density and size of flowers improve tremendously.” The company now expects that by early 2020 it will be producing over 110,000 kg/year from fully funded operations. Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…